BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 32667665)

  • 1. Transcriptome-based drug repositioning for coronavirus disease 2019 (COVID-19).
    Jia Z; Song X; Shi J; Wang W; He K
    Pathog Dis; 2020 Jun; 78(4):. PubMed ID: 32667665
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of saquinavir as a potent inhibitor of dimeric SARS-CoV2 main protease through MM/GBSA.
    Bello M; Martínez-Muñoz A; Balbuena-Rebolledo I
    J Mol Model; 2020 Nov; 26(12):340. PubMed ID: 33184722
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Sachdeva C; Wadhwa A; Kumari A; Hussain F; Jha P; Kaushik NK
    OMICS; 2020 Oct; 24(10):568-580. PubMed ID: 32757981
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug repositioning is an alternative for the treatment of coronavirus COVID-19.
    Serafin MB; Bottega A; Foletto VS; da Rosa TF; Hörner A; Hörner R
    Int J Antimicrob Agents; 2020 Jun; 55(6):105969. PubMed ID: 32278811
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In Silico Insights into the SARS CoV-2 Main Protease Suggest NADH Endogenous Defences in the Control of the Pandemic Coronavirus Infection.
    Martorana A; Gentile C; Lauria A
    Viruses; 2020 Jul; 12(8):. PubMed ID: 32722574
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Approaching coronavirus disease 2019: Mechanisms of action of repurposed drugs with potential activity against SARS-CoV-2.
    Lisi L; Lacal PM; Barbaccia ML; Graziani G
    Biochem Pharmacol; 2020 Oct; 180():114169. PubMed ID: 32710969
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A protein interaction map identifies existing drugs targeting SARS-CoV-2.
    Cava C; Bertoli G; Castiglioni I
    BMC Pharmacol Toxicol; 2020 Sep; 21(1):65. PubMed ID: 32883368
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Repurposing old drugs as antiviral agents for coronaviruses.
    Yang CW; Peng TT; Hsu HY; Lee YZ; Wu SH; Lin WH; Ke YY; Hsu TA; Yeh TK; Huang WZ; Lin JH; Sytwu HK; Chen CT; Lee SJ
    Biomed J; 2020 Aug; 43(4):368-374. PubMed ID: 32563698
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs.
    Jeon S; Ko M; Lee J; Choi I; Byun SY; Park S; Shum D; Kim S
    Antimicrob Agents Chemother; 2020 Jun; 64(7):. PubMed ID: 32366720
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identify potent SARS-CoV-2 main protease inhibitors via accelerated free energy perturbation-based virtual screening of existing drugs.
    Li Z; Li X; Huang YY; Wu Y; Liu R; Zhou L; Lin Y; Wu D; Zhang L; Liu H; Xu X; Yu K; Zhang Y; Cui J; Zhan CG; Wang X; Luo HB
    Proc Natl Acad Sci U S A; 2020 Nov; 117(44):27381-27387. PubMed ID: 33051297
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Broad Spectrum Antiviral Agent Niclosamide and Its Therapeutic Potential.
    Xu J; Shi PY; Li H; Zhou J
    ACS Infect Dis; 2020 May; 6(5):909-915. PubMed ID: 32125140
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Research progress on repositioning drugs and specific therapeutic drugs for SARS-CoV-2.
    Fan S; Xiao D; Wang Y; Liu L; Zhou X; Zhong W
    Future Med Chem; 2020 Sep; 12(17):1565-1578. PubMed ID: 32638628
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Trials of Repurposed Antivirals for SARS-CoV-2.
    Martinez MA
    Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32631826
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiviral therapy for coronavirus disease 2019.
    Gong S; Su J; Yan X; Li F; Hu L; Liu S
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2020 May; 45(5):598-602. PubMed ID: 32879113
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Computational guided drug repurposing for targeting 2'-O-ribose methyltransferase of SARS-CoV-2.
    Sharma K; Morla S; Goyal A; Kumar S
    Life Sci; 2020 Oct; 259():118169. PubMed ID: 32738360
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Putative SARS-CoV-2 M
    Mazzini S; Musso L; Dallavalle S; Artali R
    Molecules; 2020 Aug; 25(16):. PubMed ID: 32824454
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of antiviral combination therapy in symptomatic patients of Covid-19 infection - a randomised controlled trial (SEV-COVID Trial): A structured summary of a study protocol for a randomized controlled trial.
    Panda PK; Bandyopadhyay A; Singh BC; Moirangthem B; Chikara G; Saha S; Bahurupi YA
    Trials; 2020 Oct; 21(1):866. PubMed ID: 33081849
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Purposing Saikosaponins for the treatment of COVID-19.
    Bahbah EI; Negida A; Nabet MS
    Med Hypotheses; 2020 Jul; 140():109782. PubMed ID: 32353743
    [No Abstract]   [Full Text] [Related]  

  • 19. Optimization Rules for SARS-CoV-2 M
    Stoddard SV; Stoddard SD; Oelkers BK; Fitts K; Whalum K; Whalum K; Hemphill AD; Manikonda J; Martinez LM; Riley EG; Roof CM; Sarwar N; Thomas DM; Ulmer E; Wallace FE; Pandey P; Roy S
    Viruses; 2020 Aug; 12(9):. PubMed ID: 32859008
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The potential of drug repositioning as a short-term strategy for the control and treatment of COVID-19 (SARS-CoV-2): a systematic review.
    Lima WG; Brito JCM; Overhage J; Nizer WSDC
    Arch Virol; 2020 Aug; 165(8):1729-1737. PubMed ID: 32514689
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.